Sugi Predict

Sugi Predict / Compounds / SCHEMBL2863760

SCHEMBL2863760

SCHEMBL2863760

COc1cc(OCC(=O)O)c2c(c1)[nH]c(=O)c1c(N)n(-c3ccccc3C)nc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MPO P05164 1/20 0.37
▸ PDE5A O76074 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ BRD4 O60885 1/20 0.34
▸ PARP1 P09874 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ TDP2 O95551 1/20 0.34
▸ PPARD Q03181 5/20 0.34
▸ SLC16A3 O15427 1/20 0.34
▸ SLC16A1 P53985 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ ABL1 P00519 1/20 0.34
▸ LCK P06239 1/20 0.34
▸ FYN P06241 1/20 0.34
▸ LYN P07948 1/20 0.34
▸ SRC P12931 1/20 0.34
▸ MAPK14 Q16539 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2861602 0.91 FABP3 (0.40) PDE5ABRD4PARP1PTPN1
SCHEMBL2868304 0.91 THRB (0.35) THRBBRD4PARP1HTTKMT2A
SCHEMBL2871102 0.89 MMP13 (0.38) PDE5ABRD4HTTKMT2A
SCHEMBL2863158 0.88 ABCG2 (0.43) PDE5ABRD4PARP1HTTKMT2A
SCHEMBL2869345 0.88 BRD4 (0.38) PDE5ABRD4PARP1HTTKMT2A
SCHEMBL2865147 0.88 BRD4 (0.36) PDE5ABRD4PARP1HTTKMT2A
SCHEMBL2862702 0.88 SCN9A (0.39) PDE5ABRD4PARP1HTTKMT2A
SCHEMBL2869185 0.87 GAA (0.42) KMT2APOLBSMN1; SMN2
SCHEMBL2865045 0.87 NOTUM (0.36) THRBKMT2APOLBSMN1; SMN2
SCHEMBL2858318 0.87 PDE2A (0.35) PDE5ABRD4PARP1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 — — US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 — — US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 — — US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 — — US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 — — US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 — — US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 MPO 3257/4885PDE5A 1718/4885THRB 825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.